Luteolin
(Synonyms: 木犀草素; Luteoline; Luteolol; Digitoflavone) 目录号 : GN10370
木犀草素（Luteolin）是一种黄酮类化合物，具有抗炎、抗氧化、抗癌等多种功能。Luteolin是一种有效的核因子红细胞2相关因子2（Nrf2）抑制剂。
Cas No.:491-70-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
Cell lines | NCI-H460 cells |
Preparation Method | Cells were seeded into 96 well plates and were treated with 0, 20, 40, 80 or 160µM luteolin for 24 h at 37°C. |
Reaction Conditions | 0, 20, 40, 80 or 160µM; 24h |
Applications | Luteolin inhibits the viability of NCI-H460 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Wistar rats |
Preparation Method | Rats were fed a high carbohydrate/high fat diet (30% carbohydrate and 42% fat) daily for 12 weeks to induce nonalcoholic steatohepatitis (NASH). Luteolin (10, 25, 50 or 100 mg/kg/day) was administered as a suspension (10% w/v in 0.9% NaCl) using an oral gavage. |
Dosage form | 10, 25, 50 or 100 mg/kg/day; p.o. |
Applications | Luteolin to reduce activity of ALT and AST and to decrease levels of bilirubin, hyaluronic acid and malondialdehyde significantly. |
References: [1] Ma L, Peng H, Li K, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis[J]. Molecular medicine reports, 2015, 12(3): 4196-4202. [2]Abu-Elsaad N, El-Karef A. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin[J]. Pharmacological Reports, 2019, 71: 688-694. | |
Luteolin is a flavonoid compound with multiple functions such as anti-inflammatory, antioxidant, and anti-cancer[1, 2]. Luteolin is an effective inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2)[3].
In vitro, Luteolin (0-160µM) treatment of NCI-H460 cells for 24h inhibited cell viability in a concentration-dependent manner, induced cell cycle arrest at the S phase, increased the protein expression level of apoptosis regulatory proteins, and also inhibited cell migration[4]. Luteolin (0.05, 0.1, 5μM) treatment of rat bone marrow mesenchymal stem cells (BMSC) for 24-72h activated the PI3K/Akt signaling pathway and promoted BMSC osteogenic differentiation[5].
In vivo, oral administration of Luteolin (10, 25, 50, 100 mg/kg/day) to treat rats with nonalcoholic steatohepatitis (NASH) significantly reduced the levels of serum liver function biomarkers (ALT, AST, total bilirubin), hyaluronic acid, and malondialdehyde, and also reduced the levels of proinflammatory factors IFN-γ, TNF-α, IL-1α, and IL-18[6]. Luteolin (50, 100 mg/kg/day) to treat rats with cognitive impairment induced by infusion of Aβ (1-40) peptide significantly improved Aβ-induced spatial learning and spatial working memory impairment and cognitive impairment, increased the levels of SOD and GSH-Px in hippocampal homogenate, and reduced the level of MDA[7].
References:
[1] Coleta M, Campos M G, Cotrim M D, et al. Assessment of luteolin (3′, 4′, 5, 7-tetrahydroxyflavone) neuropharmacological activity[J]. Behavioural brain research, 2008, 189(1): 75-82.
[2] Ziyan L, Yongmei Z, Nan Z, et al. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models[J]. Planta medica, 2007, 73(03): 221-226.
[3] Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs[J]. Free Radical Biology and Medicine, 2011, 50(11): 1599-1609.
[4] Ma L, Peng H, Li K, et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis[J]. Molecular medicine reports, 2015, 12(3): 4196-4202.
[5] Liang G, Zhao J, Dou Y, et al. Mechanism and experimental verification of luteolin for the treatment of osteoporosis based on network pharmacology[J]. Frontiers in Endocrinology, 2022, 13: 866641.
[6] Abu-Elsaad N, El-Karef A. Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin[J]. Pharmacological Reports, 2019, 71: 688-694.
[7] Yu T X, Zhang P, Guan Y, et al. Protective effects of luteolin against cognitive impairment induced by infusion of Aβ peptide in rats[J]. International Journal of Clinical and Experimental Pathology, 2015, 8(6): 6740.
木犀草素（Luteolin）是一种黄酮类化合物，具有抗炎、抗氧化、抗癌等多种功能[1, 2]。Luteolin是一种有效的核因子红细胞2相关因子2（Nrf2）抑制剂[3]。
在体外，Luteolin（0-160µM）处理NCI-H460细胞24h，以浓度依赖性方式抑制了细胞活力，诱导了细胞周期停滞在S期，增加了凋亡调节蛋白的蛋白表达水平，还对细胞的迁移具有抑制作用[4]。Luteolin（0.05、0.1、5μM）处理大鼠骨髓间充质干细胞（BMSC）24-72h，激活了PI3K/Akt信号通路促进BMSC成骨分化[5]。
在体内，Luteolin（10、25、50、100 mg/kg/day）通过口服治疗非酒精性脂肪性肝炎（NASH）大鼠，可显著降低血清中肝功能的生物标志物（ALT、AST、总胆红素）、透明质酸和丙二醛的含量，还降低了促炎因子IFN-γ、TNF-α、IL-1α和IL-18水平[6]。Luteolin（50、100 、200mg/kg/day）通过口服治疗输注Aβ（1-40）肽引起的认知障碍模型大鼠，显著改善Aβ引起的空间学习和空间工作记忆损伤以及认知能力损伤，增加了海马体匀浆中SOD和GSH-Px的水平，同时降低了MDA的水平[7]。
| Cas No. | 491-70-3 | SDF | |
| 别名 | 木犀草素; Luteoline; Luteolol; Digitoflavone | ||
| 化学名 | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | ||
| Canonical SMILES | C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O | ||
| 分子式 | C15H10O6 | 分子量 | 286.24 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS (pH 7.2) (1:5): 1 mg/ml,DMSO: 10 mg/ml,Ethanol: 5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。